Interest of TTC for the Early Diagnosis of Acute Myocardial Infarction at Autopsy

Last updated: June 10, 2021
Sponsor: University Hospital, Montpellier
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congestive Heart Failure

Heart Disease

Coronary Artery Disease

Treatment

N/A

Clinical Study ID

NCT04924426
RECHMPL21_0283
  • Ages > 18
  • All Genders

Study Summary

Ischemic heart disease is the leading cause of death worldwide and the leading cause of sudden cardiac death. However, its post-mortem diagnosis is particularly difficult because the gross examination of the heart is usually normal at the autopsy . The diagnosis is therefore often based on a set of indirect arguments, such as the patient's medical and clinical history and the degree of occlusion of the coronary arteries. The formal diagnosis of acute myocardial infarction (AMI) currently relies on standard histological examination. However, histological findings often require a prolonged survival time of several hours to be highlighted. Triphenyltetrazolium chloride (TTC) is a salt that reacts with lactate dehydrogenases contained in still viable myocardial cells, forming a red pigment visible to the naked eye, (1,3,5 triphenylformazan). Ischemia-induced cell death, which occurs within minutes of the causative event, is responsible for the leakage of lactate deshydrogenase into the extracellular medium and thus results in the absence of formazan formation in the infarcted area, which displays an easily identifiable pale unstained color. It has been suggested that the use of TTC would allow the identification of MI as early as one hour of survival in animal models, before the usual macroscopic and microscopic signs are visible. It could therefore represent an attractive forensic tool for the early diagnosis of AMI at the autopsy.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Adult patients autopsied at the Forensic Institute of the CHU of MONTPELLIER whoseante-mortem (medical history, cardiovascular risk factors, clinical history) andautopsy data (significant coronary stenosis associated or not with an endoluminalthrombus, scars of old infarction, absence of other identified cause of death) suggestAMI as the cause of death.
  • Known survival time and postmortem interval.

Exclusion

Exclusion criteria:

  • Putrefied bodies

Study Design

Total Participants: 40
Study Start date:
May 01, 2021
Estimated Completion Date:
August 30, 2022

Connect with a study center

  • Uhmontpellier

    Montpellier, 34295
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.